LSE:DNL (Diurnal Group plc)

Diurnal Group PLC is a specialty pharmaceutical company developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism, and Hypothyroidism. The company has two products in late-stage clinical development targeting Adrenal diseases; Chronocort to be used for the treatment of Congenital Adrenal Hyperplasia and Adrenal Insufficiency in Adults and Infacort which is to be used for the same conditions in children. Its main country of operation is the United Kingdom.